ATORVASTATIN 10mg. IP + CLOPIDOGREL 75mg. IP + ASPIRIN 75mg. IP

A combination drug of blood-thinning agents and cholesterol-lowering agents for atherosclerotic patients suffering from various heart diseases. (Mahmoud Mohamed Issa, 2013) Works by preventing platelets from forming clots that may cause a heart attack or stroke. Blocks the platelet adenosine diphosphate receptor, and powerfully inhibits platelet activation, degranulation, and aggregation. (Jehangir N Din, 2005) A powerful compound that has the ability to reduce cardiovascular disease by stopping the growth of plaques in artery walls. (Ursula Gresser, 2004) Demonstrates considerable success at reducing thrombotic complications of acute coronary syndrome and percutaneous coronary intervention. (Abu-Fadel, 2009) Significantly reduces total cholesterol, triglyceride, and low-density lipoprotein cholesterol in hypercholesterolemia patients. (Chumpol Piamsomboon 1, 2002) Prevents cardiovascular events in patients at higher risk of cardiovascular disease, as well as in those with acute coronary syndrome. (Christopher W. Walker, 2007) Exerts antiplatelet effects by inhibiting thromboxane A2 production and adenosine diphosphate-induced platelet aggregation pathways. (Hani Jneid, 2003) Reduces the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. (J Floris S Logman, 2010) Decreases levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, triglyceride, and very low-density lipoprotein (VLDL)-cholesterol and increases high-density lipoprotein (HDL)-cholesterol in patients with a wide variety of dyslipidaemias. (H S Malhotra, 2001) Offers additional benefits for those patients at high risk and those with established cardiovascular disease. (T T Keller, 2007)